Kala Bio, Inc. (KALA): Cash & Equivalents
$7.56M
As of 2025-12-31
$229.0K
As of 2026-06-30
-52.5%
3-year compound annual growth
-37.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.56M | -85.2% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $51.18M | +0.6% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $50.90M | -27.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $70.50M | -23.5% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $92.14M | +19.2% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $77.26M | -9.6% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $85.45M | n/a | 2021-02-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.56M | -85.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare KALA, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗